However, the growth disadvantage of Ankrd52-null tumors was abolished when implanted to WT mice (Supplementary Fig. 5a), suggesting that loss of ANKRD52 enabled cancer cells to escape T cell immunity in vivo, thereby offsetting their intrinsic growth deficiency. Here, ANKRD52 is linked to cancer.